PT-141 Dosage Guide: Complete Guide

What Is PT-141?

PT-141 (bremelanotide) is a synthetic peptide that activates melanocortin-4 receptors in the brain to enhance sexual desire and arousal . It's FDA-approved as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women and is also used off-label for male sexual dysfunction.

Getting the dose right is important with PT-141. Unlike some peptides where dosing is highly variable and based on limited data, PT-141 has an established dosing protocol from clinical trials. This guide will walk you through the standard dosing parameters, timing considerations, and what your physician may adjust based on your individual needs. For a broader overview, see our PT-141 benefits guide.

FDA-Approved Dosing Protocol

The dosing protocol established through Phase 3 clinical trials and approved by the FDA is straightforward:

• Dose: 1.75 mg per injection
• Route: Subcutaneous injection (under the skin), typically in the abdomen
• Timing: At least 45 minutes before anticipated sexual activity
• Maximum frequency: No more than once every 24 hours
• Monthly limit: No more than 8 doses per month

This protocol was validated in the RECONNECT trials, which demonstrated both efficacy and safety at the 1.75 mg dose level. The monthly limit of 8 doses is based on the clinical trial protocol and is designed to balance effectiveness with safety considerations.

Why 1.75 mg?

The 1.75 mg dose was selected through dose-finding studies conducted during Phase 2 development. Researchers tested multiple dose levels and found that 1.75 mg provided the best balance of efficacy and tolerability .

From the FormBlends catalog

PT-141 (Bremelanotide)

for women with low sexual desire. · From $189/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.

View PT-141 (Bremelanotide) →

At lower doses, the effects on desire were less consistent. At higher doses, side effects (particularly nausea) increased substantially without proportional gains in efficacy. The 1.75 mg dose hit the therapeutic window where benefit outweighed side effects for the greatest number of patients.

Timing Considerations

The timing of PT-141 administration matters because the peptide needs time to reach its central targets in the brain:

• Minimum lead time: 45 minutes before anticipated sexual activity
• Onset of effects: Most users report effects beginning within 30 to 60 minutes after injection
• Duration of effects: Effects can last for several hours, with some users reporting effects persisting up to 12 hours or longer
• Peak effect: Typically occurs within 1 to 2 hours after administration

Individual response times vary. Some people find that administering PT-141 60 to 90 minutes before activity works better than the minimum 45-minute window. Your physician can help you refine the timing based on your experience.

Dosing for Men

While PT-141 is FDA-approved only for women with HSDD, physicians may prescribe it off-label for men with sexual dysfunction. Dosing in the male clinical studies varied, but common protocols used in clinical practice include:

• Typical dose: 1.75 mg to 2 mg subcutaneously, consistent with the studied dose range
• Timing: 45 to 60 minutes before anticipated sexual activity
• Frequency: On-demand use, with similar frequency guidelines to the approved protocol

Some physicians start men at the standard 1.75 mg dose and adjust based on response and tolerability. Because male use is off-label, your physician's guidance is especially important here.

Adjusting Your Dose

While the standard dose is 1.75 mg, your physician may consider adjustments based on several factors:

Starting Lower

If you're concerned about nausea (the most common side effect), your physician may suggest starting at a lower dose, such as 1 mg, to assess your tolerance before moving to the full dose. This isn't part of the standard protocol but is a common approach used in clinical practice to improve patient comfort.

Factors That May Influence Dosing

• Body weight: While PT-141 dosing isn't weight-based in the approved protocol, individual body composition may influence response
• Nausea tolerance: Patients experiencing significant nausea may benefit from a gradual titration approach
• Other medications: Drug interactions may require dosing adjustments or additional spacing between medications
• Kidney function: Moderate to severe renal impairment may affect PT-141 clearance, and dosing adjustments may be warranted

Never adjust your dose without consulting your physician. Self-adjusting peptide doses can lead to subtherapeutic effects or increased side effects.

What Happens If You Take Too Much

Taking more than the recommended dose increases the likelihood and severity of side effects, particularly nausea and blood pressure changes. In clinical studies, higher doses did not produce proportionally better results but did increase adverse effects .

If you accidentally administer more than your prescribed dose, monitor for:

• Severe nausea or vomiting
• Significant flushing
• improved blood pressure
• Dizziness

Contact your physician or seek medical attention if symptoms are severe or persistent.

Frequency and Cycling

PT-141 is designed for on-demand use and isn't intended for daily administration. The clinical trial protocol limited use to no more than 8 doses per month. This limit exists for several reasons:

• Receptor desensitization: Melanocortin receptors can become less responsive with frequent stimulation, potentially reducing the peptide's effectiveness over time
• Safety margin: The 8-dose monthly limit reflects the maximum frequency studied and found safe in clinical trials
• Nausea management: Spacing doses allows recovery between uses

Some physicians recommend using PT-141 no more than 1 to 2 times per week to maintain receptor sensitivity and minimize side effects. Your physician will set the appropriate frequency for your situation.

Safety and Side Effects

Proper dosing is one of the most important factors in managing PT-141 side effects. The most common side effects at the approved dose include nausea (approximately 40%), flushing (approximately 20%), and headache (approximately 11%) .

For a complete breakdown of safety information, see our PT-141 side effects guide. For injection technique guidance, see our PT-141 how to inject guide.

How FormBlends Can Help

Getting the right dose of PT-141 requires a physician who understands both the clinical data and your individual health profile. At FormBlends, our telehealth platform provides:

• A thorough medical evaluation to determine appropriate dosing
• Pharmaceutical-grade PT-141 from licensed pharmacies
• Clear instructions on timing, technique, and frequency
• Dose adjustment guidance based on your response and tolerability
• Ongoing physician access for questions and monitoring

We don't use a one-size-fits-all approach. Your physician will tailor the protocol to your needs.

Frequently Asked Questions

What is the standard dose of PT-141?

The FDA-approved dose is 1.75 mg administered subcutaneously. This dose was established through clinical trials as the optimal balance between efficacy and tolerability.

Can I take PT-141 every day?

No. PT-141 is designed for on-demand use, not daily administration. It shouldn't be used more than once every 24 hours or more than 8 times per month. Daily use may lead to receptor desensitization and increased side effects.

How long before sex should I take PT-141?

PT-141 should be administered at least 45 minutes before anticipated sexual activity. Many users find that 60 to 90 minutes provides optimal results. Effects can last for several hours after onset.

What if I don't feel anything at 1.75 mg?

Not everyone responds to the same dose. If you don't notice effects at 1.75 mg, discuss this with your physician. They may adjust the dose, suggest changes in timing, or explore whether PT-141 is the right approach for your situation. Don't increase the dose on your own.

Is dosing different for men and women?

The FDA-approved dose of 1.75 mg was established in studies of premenopausal women. Male dosing in clinical research has used similar ranges. Your physician will determine the right dose based on your sex, health profile, and treatment goals.